Lexical and acoustic speech features relating to Alzheimer's disease pathology

Sunghye Cho[a], Katheryn A.Q. Cousins[b], Sanjana Shellikeri[b], Sharon Ash[b], David J. Irwin[b], Mark Liberman[a], Murray Grossman[b], Naomi Nevler[b]

a. Linguistic Data Consortium, University of Pennsylvania, Philadelphia, PA 19104, USA

b. Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA 19104, USA

Correspondence to:

Sunghye Cho

Linguistic Data Consortium

3600 Market Street

Philadelphia, PA 19104

Email: csunghye@ldc.upenn.edu

15   **Key words**: Alzheimer's Disease pathology; Alzheimer's Disease; Logopenic variant primary

16   progressive aphasia; speech characteristics; automatic speech processing

Abstract

INTRODUCTION: In this study, we compared digital speech features of AD and lvPPA

patients in a biologically confirmed cohort and related them to specific neuropsychiatric test

scores and CSF proteins.

METHODS: We extracted language variables with automated lexical and acoustic pipelines

from oral picture descriptions of 44 AD and 21 lvPPA patients with autopsy or CSF confirmation

of AD pathology. We correlated distinct speech features with MMSE and BNT test scores and

CSF p-tau levels.

RESULTS: LvPPA patients produced fewer verbs, adjectives, and more fillers with lower

lexical diversity and higher pause rate than AD. Both groups showed some shared language

impairments compared with normal speakers.

DISCUSSION: Our speech measures captured differences in speech between the two

phenotypes. Also, shared speech markers were linked to the common underlying pathology. This

work demonstrates the potential of natural speech analysis in detecting underlying AD

pathology.

Acknowledgements

The authors thank the patients and caregivers who participated in this study. Funding: This study was funded by grants from the National Institute of Health (AG066597, AG054519, NS109260, P30 AG072979), Alzheimer's Association (AACSF-18-567131, AARF-D-619473, AARF-D-619473-RAPID), Department of Defense (PR192041).

Declaration of interest

Dr. Grossman participates in clinical trials sponsored by Alector, Eisai and Biogen that are unrelated to this study. He also receives research support from Biogen and Avid that is unrelated to this study, and research support from NIH. Dr. Mark Liberman serves on the Scientific Advisory Board for Baidu Research, USA, and is a co-editor of the Annual Review of Linguistics. All other authors have nothing to disclose.

1. Background

Speech production is a complex behavior, involving coordinated activation of multiple brain regions. Thus, examining speech production provides potential opportunities to identify neurodegenerative disease markers that are sensitive to specific phenotypes. Since Alzheimer's disease (AD) accounts up to 80% of patients with dementia,[1] much attention has been paid to cognitive and linguistic profiling of AD. Language produced by amnestic AD patients was found to be "empty" with abundance of nonspecific words, circumlocutions, and sparse content.[2]

Logopenic variant primary progressive aphasia (lvPPA) is a recently identified PPA variant,[3,4] which is an atypical, non-amnestic manifestation of AD,[3,5–9] with over 50% of autopsied cases associated with underlying AD pathology.[9,10] Since the identification of this PPA variant, many studies have been dedicated to characterizing its linguistic features. Previous studies have shown that lvPPA patients speak slowly with impaired lexical access,[11] and have poor phonemic discrimination[12] with limited auditory-verbal short-term memory, naming impairment,[4,5] and dysfluencies.[13]

Previous studies of neurodegenerative patients suggest that language features are useful as a screening tool[14–18], because speech is easy to collect non-invasively, and it is sensitive to cognitive impairments. Despite the shared pathology of AD and lvPPA, previous studies have focused on the linguistic profiling of these two syndromes separately. With few comparative studies, this leaves an important gap in the literature. Most previous quantitative work has focused on measures such as the Boston Naming Test (BNT) that assess lexical retrieval during confrontation naming of an object. However, descriptions of natural, connected speech in AD and lvPPA are frequently informal. In this study, we identified similarities and differences

between AD and lvPPA patients with biological confirmation of underlying AD pathology, by

analyzing digitized, natural speech samples with reliable and reproducible automated methods.

Based on previous studies, we hypothesized that lvPPA patients would produce more dysfluent

speech with more limited lexical content than AD patients. We also hypothesized that AD and

lvPPA patients would share linguistic similarities, including decreased speech production. We

associated language variables with clinical test scores and CSF analytes for additional validation

and specific mechanistic clarification.

74 2. Methods

75 2.1 Participants

We examined oral picture descriptions that were collected from 93 participants in the

Department of Neurology at the Hospital of the University of Pennsylvania. Forty-four

participants had amnestic AD, and 21 were lvPPA patients with confirmed underlying AD

pathology, based on autopsy (n=15; 4 lvPPA and 11 AD patients) or on cerebrospinal fluid

(CSF) analytes levels (n=50; 17 lvPPA and 33 AD patients; phosphorylated Tau (p-Tau)/beta-

amyloid 42 (Aβ) ≥ 0.09[19] *and* total Tau/Aβ ≥ 0.34[20]). Twenty-eight matched elderly healthy

controls (HC) were included as a control group. Participants with other neurological, psychiatric,

or medical conditions that could affect cognition were excluded.

Table 1 shows the demographic and clinical characteristics of the participants. The groups did

not differ in age, sex, or education level. The patient groups did not differ from each other in

disease duration (p=0.45), the Mini-Mental State Exam (MMSE; p=0.12), BNT (p=0.32), CSF p-

Tau (p=0.81), Aβ (p=0.36), or p-Tau/Aβ ratio levels (p=0.66).

Table 1: Demographic and clinical characteristics of participants.

	AD (N=44)	lvPPA (N=21)	HC (N=28)	p value
Age (years)	62.0 (8.0)	64.1 (8.2)	65.9 (5.9)	0.098
Education (years)	16.0 (2.6)	16.1 (3.2)	15.9 (2.6)	0.965
Sex				0.986
Female	24 (54.5%)	11 (52.4%)	15 (53.6%)	
Male	20 (45.5%)	10 (47.6%)	13 (46.4%)	
Disease Duration (years)	3.7 (2.6)	3.4 (1.5)	NA	
MMSE*	21.1 (4.8)	23.0 (4.2)	29.2 (1.0)	< 0.001
BNT*	20.1 (8.4)	18.6 (8.6)	27.9 (2.7)	< 0.001
CSF p-Tau	38.5 (20.1)	38.4 (16.0)	NA	
CSF Aβ	139.9 (36.2)	135.0 (26.2)	415.0 (NA)	< 0.001
CSF p-Tau/Aβ	0.3 (0.2)	0.3 (0.2)	NA	

89 NOTE: *AD and lvPPA patients did not differ in MMSE or BNT.

90 Abbreviations: AD = Alzheimer's disease, lvPPA = logopenic variant primary progressive

91 aphasia, HC = healthy controls; MMSE = Mini-mental State Exam; BNT = Boston Naming Test;

92 CSF = Cerebrospinal fluid; p-Tau = phosphorylated Tau; Aβ = beta-amyloid 42.

2.2 Data collection

To optimize reliability and reproducibility, we digitally recorded the participants' descriptions of the Cookie Theft picture from the Boston Diagnostic Aphasia Examination.[21] Descriptions were about 1 minute long. Recordings were orthographically transcribed. The earliest recording of each participant was analyzed with our lexical and acoustic pipelines, as described below.

2.3 Lexical pipeline

We automatically tagged the part-of-speech (POS) category of all tokens, using spaCy[22] with its large language model ('en_core_web_lg') for English. The number of tense-inflected verbs was calculated by summing the number of modal auxiliaries, past-tense, and present-tense verbs. Dysfluency markers, including fillers, repetitions, and partial words, were counted separately. The count of each POS category, tense-inflected verbs, and dysfluency markers were converted to counts per 100 words, controlling for the total number of words per participant.

We rated each word for concreteness,[23] semantic ambiguity,[24] frequency,[25] age of acquisition (AoA),[26] familiarity,[26] and word length by the number of phonemes,[27] based on published norms. We calculated the mean scores of these measures for content words (nouns, verbs, adjectives, and adverbs) per participant.

Lastly, we measured lexical diversity, using the moving-average type-token ratio (MATTR),[28] which has been described as one of the most reliable measures for calculating lexical diversity.[29] The window length was set at 15 words. Detailed description of the lexical pipeline and validation of the POS tagging accuracy has been previously published.[30]

2.4 Acoustic pipeline

We employed an in-house speech activity detector (SAD) to segment audio recordings into speech segments and silent pauses. We visually reviewed the segments, and non-speech segments at the beginning and end of each recording and interviewer's prompts were excluded from the analysis.

Using the SAD output, we calculated five duration-related measurements, including mean speech segment duration, mean pause segment duration, total speech time, percent of speech, and pause rate per minute. We summed the number of syllables of all words from the published norm[27] and computed articulation rate as the number of syllables per second.

Additionally, we pitch-tracked all speech segments with Praat.[31] To normalize physiological differences in pitch (f0), we converted the pitch values from Hz to semitones (st) using the 10th pitch percentile of each participant as a baseline: $st=12*\log_2(f0/baseline\ f0)$. We used the converted 90th percentile as a measure of the pitch range of each speaker. Detailed description of the acoustic pipeline has been published previously,[32] and the list of all analyzed features is included in the Appendix.

2.5 CSF analysis

Forty-two (30 AD and 12 lvPPA) patients had CSF biomarkers collected within one year of the Cookie Theft recording (mean interval = 4.7 months ± 3.5), including Aβ and p-Tau. This subset did not differ demographically or clinically from the larger group of patients. CSF was analyzed with two platforms, Luminex xMAP or Innotest ELISA, which was then transformed to the Luminex scale.[33] We previously related CSF p-Tau levels directly to cerebral tau burden in our

135   autopsy cohort.[33] The AD and lvPPA subset groups did not differ in age (p=0.64), sex (p=0.99),

136   education (p=0.82), disease duration (p=0.75), or the time difference between CSF sample

137   collection and the Cookie Theft recording (p=0.43). To determine the association of language

138   features with in vivo measures of pathology, we examined the relationship between our language

139   variables and the two CSF biomarkers of Aβ and p-Tau.

140   2.6 Statistical considerations

To compare the groups, we tested if requirements for parametric tests were met with a Levene's

test. If the data met the requirements for parametric tests, we performed an Analysis of Variance.

If not, we performed a Kruskal-Wallis test. We visually assessed residuals of the models to make

sure the data was suitable for linear modelling. When a group difference was significant, we

additionally performed a posthoc pairwise t-test or pairwise Wilcoxon rank sum test for pairwise

group comparisons, adjusting p-values for multiple group comparisons (n=3) with the false

discovery rate (fdr). We reported the effect size of each group comparison using Cohen's d.

Patients' language variables were z-scored using HC's mean and standard deviation. These z-

scores were used for visualization and linear regressions to estimate relations of our language

variables and clinical ratings. We did not use z-scores to determine significant group differences

with Z-tests, since the test statistic in some variables did not follow a normal distribution.

The z-scored language variables that showed significant group differences were associated with

patients' MMSE and BNT scores to investigate the relations of our language features to clinical

ratings of cognitive and language impairment. To examine potential interactions, we included

phenotype as an interaction term (MMSE/BNT ~ language variable*phenotype). P-values were

adjusted with fdr.

To validate our findings with levels of specific CSF biomarkers, we correlated patients' CSF

analyte levels to the language variables using Pearson correlation tests. CSF p-Tau levels were

log-transformed to normalize the data. We also checked if patients' clinical phenotype and the

time difference between Cookie Theft recording and CSF sample collection were significant

factors with linear regression models. Since the two factors were not significant, we only

reported the results of simple correlations to simplify the models. All statistical analyses were

performed with R version 4.1.0[34] and RStudio version 1.4.1717.[35]

164   2.7 Ethics

165   The Institutional Review Board of the Hospital of the University of Pennsylvania approved the

166   study of human subjects, and all participants agreed to participate in the study by written

167   consent. All digital data was stored in secured HIPAA-compliant servers and handled by

168   personnel trained in PPI protection.

3. Results

3.1 Differences between amnestic AD and lvPPA patients

Figure 1: Speech differences between lvPPA and amnestic AD. For ease of visualization, z-scored values compared to HC mean and standard deviation are plotted. Horizontal black line indicates HC's mean. Abbreviations: AD = Alzheimer's disease, lvPPA = logopenic variant primary progressive aphasia, HC = healthy controls

LvPPA patients produced fewer tense-inflected verbs compared to AD (p=0.001, $|d|$=0.94) and HC (p=0.048, $|d|$=0.61; Fig.1A). AD patients' tense-inflected verb counts did not significantly differ from HC (p=0.124, $|d|$=0.4). Patients with lvPPA showed lower lexical diversity than AD

(p=0.05, $|d|$=0.52) and HC (p=0.005, $|d|$=1.02), yet AD patients did not differ from HC (p=0.149,

$|d|$=0.39; Fig.1B). LvPPA patients produced fewer adjectives than AD patients (p=0.019,

$|d|$=0.66) and HC (p<0.001, $|d|$=1.72); AD patients also produced fewer adjectives than HC

(p=0.003, $|d|$=0.75; Fig.1C). Thus, both patient groups were impaired in their adjective

production, but lvPPA was more severely impaired compared with AD.

LvPPA patients also produced more fillers than AD (p=0.022, $|d|$=0.6) and HC (p=0.01, $|d|$=1.06;

Fig.1D), while AD did not significantly differ from HC (p=0.383, $|d|$=0.23). Patients with lvPPA

showed a higher pause rate than AD (p=0.015, $|d|$=0.55) and HC (p<0.001, $|d|$=1.58; Fig.1E); AD

patients' pause rate was also higher than HC (p<0.001, $|d|$=1.34). Lastly, lvPPA patients

produced more partial words than HC (p=0.042, $|d|$=0.61), but lvPPA patients did not

significantly differ from AD speakers(p=0.147, $|d|$=0.3); AD patients did not differ from HC

(p=0.313, $|d|$=0.24). Thus, lvPPA speakers produced an abnormal number of partial words, while

AD speakers did not.

3.2 Impaired speech features in both AD and lvPPA

Figure 2: Impaired speech measures in both lvPPA (green) and AD (yellow). Only speech measures that were significantly different from HC (gray) are plotted, and measures were standardized based on the HC mean and standard deviation. The numbers in blue indicate z-scored values based on HC. Abbreviations: AD = Alzheimer's disease, lvPPA = logopenic variant primary progressive aphasia, HC = healthy controls

AD and lvPPA patients produced fewer prepositions and nouns than HC; patients produced shorter speech segments than HC, and their percent of speech time out of the total time was also lower than HC ($p<0.001$, $|d|>0.8$ for all comparisons). Both groups' content words were shorter, more frequent (length & frequency: $p<0.001$, $|d|>0.8$), earlier-acquired (lvPPA: $p<0.001$, $|d|=0.95$; AD: $p<0.001$, $|d|=0.56$), and more concrete (lvPPA: $p=0.028$, $|d|=0.7$, AD: $p=0.002$,

204 |*d*|=0.86) than HC's. Both patient groups produced more adverbs (lvPPA: *p*=0.029, |*d*|=0.84; AD:

205 *p*=0.029, |*d*|=0.73) and repetitions (lvPPA: *p*<0.001, |*d*|=1.39; AD: *p*<0.001, |*d*|=0.79) than HC.

206 Patients also spoke slower (lvPPA: *p*<0.001, |*d*|=1.01; AD: *p*<0.001, |*d*|=0.57), and they

207 produced fewer words in total than HC (lvPPA: *p*=0.032, |*d*|=0.7; AD: *p*=0.007, |*d*|=0.73).

3.3 Relationships to clinical measures

Figure 3: Results of linear regression models of speech masures in patients with MMSE and

BNT. Standardized estimated coefficients (x-axis) are plotted with colors: positive coefficients

are in blue and negative ones in red. P-values are adjusted with fdr. *: *p*<0.05, **: *p*<0.01, ***:

p<0.001. Abbreviations: AD = Alzheimer's disease, lvPPA = logopenic variant primary

progressive aphasia, HC = healthy controls, MMSE = Mini-mental State Exam; BNT = Boston

Naming Test

MMSE was significantly related to five language variables. Patients with lower MMSE produced

more frequent (*β*=-1.6, *p*=0.009) and shorter content words (*β*=1.75, *p*=0.001), paused more

frequently (*β*=-1.21, *p*=0.041), and produced more adverbs (*β*=-1.9, *p*=0.003) and partial words

(*β*=-1.52, *p*=0.021).

BNT was significantly associated with ten variables. Patients with lower BNT produced frequent

words (*β*=-4.36, *p*<0.001), many adverbs (*β*=-2.41, *p*=0.041), and had a high pause rate (*β*=-

2.09, *p*=0.041). Patients with lower BNT also produced fewer prepositions (*β*=2.42, *p*=0.048)

and nouns (*β*=5.18, *p*=0.003). Patients with lower BNT showed a low percent of speech

produced during the picture description (*β*=2.4, *p*=0.045), and they produced shorter (*β*=2.94,

p=0.003), less concrete (*β*=4.24, *p*=0.003), and earlier-acquired (*β*=4.69, *p*=0.003)content

words, with shorter speech segments (*β*=3.89, *p*=0.041).

Only one variable showed a significant interaction with phenotype. AD patients with lower

MMSE scores produced more adverbs (*β*=-1.9, *p*=0.003), yet lvPPA patients with lower MMSE

scores produced fewer adverbs (*β*=2.67, *p*=0.015).

3.4 CSF results

Figure 4: Significant correlations of the speech variables and CSF p-Tau levels. Abbreviations:

AD = Alzheimer's disease, lvPPA = logopenic variant primary progressive aphasia, HC =

healthy controls, CSF = Cerebrospinal fluid, p-Tau = phosphorylated Tau, Aβ = beta-amyloid 42

Patients' CSF p-Tau level correlated with lower preposition counts (r=-0.36, p=0.019), lower

noun counts (r=-0.31, p=0.047), and shorter mean speech segment durations (r=-0.33, p=0.032;

Fig.4A-C). Also, patients' p-Tau levels were inversely correlated with a higher pause rate

(r=0.34, p=0.026) and higher word frequency (r=0.33, p=0.036; Fig.4D-E). The other measures

(adverbs, partial words, tense-inflected verbs, articulation rate, lexical diversity, total words,

fillers, repetitions, adjectives, percent of speech, word length, concreteness, AoA) were not

related to patients' p-Tau levels. Aβ alone did not significantly correlate with any of the

language measures.

243   4. Discussion

LvPPA is most frequently associated with underlying AD pathology, but direct comparison of

lvPPA with amnestic AD patients has been reported rarely. The current study focuses on

characterizing the language similarities and differences between lvPPA and AD in a biologically

confirmed cohort. To optimize reliability and reproducibility, we used fully automated lexical

and acoustic analyses to characterize linguistic markers of AD pathology. We expected that

lvPPA patients with non-amnestic AD would produce more dysfluent speech with limited

vocabulary than amnestic AD patients because of lvPPA's phenotypic characteristics. Results

confirmed that lvPPA patients produced fewer adjectives and tense-inflected verbs with lower

lexical diversity than amnestic AD patients and HC. lvPPA patients also paused more frequently

and produced more fillers and partial words than HC and/or amnestic AD patients. However, we

also found that both patient groups shared impairments in some speech features relative to HC.

For example, both patient groups produced more adverbs, including words like "*there*" and

"*here*," but fewer prepositions and nouns than HC. Also, patients' content words were earlier-

acquired, shorter, more frequent, and less concrete than those of HC. Patients produced more

repetitions and fewer total words with a slower articulation rate and a shorter mean speech

duration than HC. Some of these language variables were significantly related to clinical test

scores and p-Tau levels in CSF. We discuss these findings below.

The patient groups significantly differed on six language measures: pause rate, partial words,

fillers, adjectives, tense-inflected verbs, and lexical diversity. Fillers, adjectives, tense-inflected

verbs, and lexical diversity were significantly more impaired in lvPPA than AD patients,

emphasizing the deficits in lexical retrieval and poor fluency in these patients. However, these

linguistic features distinguishing between lvPPA and amnestic AD were not related to patients'

MMSE or BNT. It is important to note that the mechanism thought to subserve retrieval of a

single word in response to a stimulus picture appears to differ from lexical retrieval during

natural connected speech.[36] It is thus critical to monitor these speech features since they are not

easily explained by more general and commonly used measures such BNT and MMSE. To our

knowledge, the result that tense-inflected verb production differed between lvPPA and AD has

not been previously reported. This finding seems to suggest that lvPPA patients produced fewer

complete sentences, assuming that there was one tense-inflected verb per inflection phrase.[37]

This would be consistent with the observation that lvPPA patients' limited auditory-verbal short-

term memory results in briefer sentences.[3,4] Frequent fillers in lvPPA were in line with previous

observations, and consistent with their limited lexical retrieval.[11,38,39] Lower adjective counts in

amnestic AD patients compared to HC have been previously reported,[40] yet we further showed

that the adjective production was more impaired in non-amnestic lvPPA than amnestic AD.

Lexical diversity has been frequently examined in the AD literature,[14,15,41,42] where previous

studies have found that AD patients' lexical diversity was lower than that of HC. We showed

that lexical diversity was even lower in lvPPA than in AD. The fact that lvPPA and AD patients

significantly differed on these measures suggests that our language variables may capture subtle

but unique phenotypic differences between lvPPA and AD. Additionally, traditional clinical

ratings such as the MMSE and BNT are relatively insensitive to these linguistic features. Also,

none of the six variables, except pause rate, correlated with CSF p-tau, and regression analyses

failed to find an interaction of p-Tau level with phenotype in the assessment of pause rate. This

suggests that these speech markers are related more narrowly to the phenotype and not

necessarily to the underlying AD pathology burden. Further studies, including the anatomic

distribution of pathology in an autopsy cohort with quantitative measures of pathological burden,

may help shed light on this issue.

Some speech measures were related to MMSE and BNT. Pause rate showed more impairment in

lvPPA than AD. This might indicate word-finding difficulty in lvPPA which could provoke

frequent pausing to recall an appropriate word from their lexicon. It could also be that lvPPA

patients spoke slowly – patients' articulation rate was lower than that of HC – due to their

difficulty in retrieving words to generate utterances. Pause rate was significantly related to both

MMSE, an indicator of general cognitive impairment, and BNT, a measure of confrontation

naming. Elevated pause rate, therefore, may reflect in part both patients' word-finding

difficulties and general cognitive impairments. Partial word count, which was impaired only in

lvPPA, only correlated with MMSE, suggesting that it reflected in part lvPPA patients' disease

severity and general cognitive impairments, but not impaired object naming.

Word-finding difficulty in AD and lvPPA has been previously noted,[11,43–48] where studies have

shown that patients had impairments in auditory-verbal short-term memory and could not recall

the phonological form of a word. However, comparative studies have not been reported to

examine if both amnestic AD and non-amnestic lvPPA patients would show word-finding

difficulty to a similar degree during natural speech. In our study, both patient groups produced

content words that were more abstract, earlier-acquired, more frequent and shorter than those of

HC, suggesting that they had difficulties in retrieving the full spectrum of lexical items needed to

describe the picture. Word frequency and length were significantly related to both MMSE and

BNT, which suggests that these lexical measures reflect in part patients' disease severity and

difficulties in lexical retrieval during confrontation naming. On the other hand, concreteness and

AoA were significantly associated only with BNT, indicating that these may be more sensitive to

word-finding difficulty in patients. AD and lvPPA patients did not significantly differ in these

measures, confirming that some degree of word-finding difficulty is present in both amnestic and

non-amnestic AD.

Adverb counts were greater in patients compared to HC. This may be related to patients

frequently using "pro-adverbs," including "*here*" and "*there*," which replaced locational

prepositional phrases. Patients typically produced utterances like "Mom is standing *here*," for

example, when HC produced "Mom is standing *in front of the sink*." Elevated adverb counts

were associated with low BNT scores in AD, suggesting that greater adverb use reflected AD

patients' difficulties in naming specific locations during natural speech. Patients' difficulty in

producing locational phrases were also partly reflected in the decreased preposition counts

compared to HC, which was also related to BNT scores. Additional work is needed to determine

if decrease preposition counts and increase adverb use are related to temporal propositions and

other features in connected speech.

Some of our language variables correlated with CSF p-Tau levels, but not with Aβ. This finding

is in line with previous findings that patients' cognitive impairment is generally not related to Aβ

levels but to accumulation of p-Tau.[49–51] Language production is one of the most essential daily

functions of humans, which needs to be taken into consideration in AD clinical trials and may

serve in monitoring response to treatment. Since our automated procedures for collecting speech

features is highly reliable and reproducible, investigations of speech variables as secondary

outcome measures should be considered in disease-modifying trials targeting tau.

The strengths of our study include that we directly compared speech features in AD and lvPPA

patients with biological evidence of underlying AD pathology. We examined natural connected

speech quantitatively using automated analyses of digitized speech samples. We inspected

language differences and similarities in these groups and showed that our language variables

could capture subtle linguistic differences between the two phenotypes, and traditional cognitive

measures such as MMSE and BNT appear to be insensitive to some of the features distinguishing

between amnestic AD and lvPPA. These methods may be useful in screening for underlying AD

pathology and monitoring disease progression and response to therapeutic interventions, because

collecting one-minute speech samples is easy, highly reproducible, and less costly and can be

collected remotely compared with other biomarkers. Future studies, testing the value of these

speech features in longitudinal datasets and developing machine learning classifiers for patient

stratification of AD pathology would be valuable. Shortcomings include the assessment of

relatively small samples, the difficulty obtaining train-test generalizability data in rare lvPPA and

early-onset AD cases such as these, the use of a single stimulus picture to elicit the speech

sample, and the absence of high resolution MRI data to assess the anatomic associates of these

linguistic features.

5. Conclusion

We implemented automated methods in analyzing acoustic and lexical characteristics of

amnestic AD and lvPPA patients' natural speech.We found speech markers that differed between

the groups. These features seemed to relate to the clinical phenotype and less so to the

underlying pathology. We also found speech markers that were shared between these two AD

phenotypes and linked to the common underlying pathology. This work demonstrates the

potential of natural speech to reflect underlying AD pathology while distinguishing between

specific phenotypes with the same pathology. Considering the cost effectiveness and reliability

of speech data, such markers could contribute to screening in AD clinical trials and longitudinal

monitoring in a more precise and inclusive way.

Appendix

Table A. List of features used in the analysis.

Feature set	Features	Example or definition
Part-of-speech categories	Nouns	*cookie*
	Tense-inflected verbs	Sum of auxiliaries, past-tense, present tense verbs
	Adjectives	*nice*
	Adverbs	*only, here*
	Conjunctions	*and*
	Determiners	*the*
	Pronouns	*she*
	Prepositions	*in, from*
	Particles	give *up*
	Interjections	*jeez*
Dysfluency markers	Fillers	*um, uh*
	Partial words	*coo-* cookie
	Repetitions	*I I* can't
	Concreteness	How concrete a word's meaning is

Feature set	Features	Example or definition
Lexical characteristics	Frequency	Log$_{10}$ scaled word frequency per million words
	Ambiguity	Number of a words' meaning in a context
	Age of acquisition	Average age when children acquire a given word
	Familiarity	Number of people who know a given word
	Word length	Number of phonemes in a word
	Lexical diversity	Average type-token ratio of all windows
Acoustic measures	Mean speech segment duration	Average of all speech segment durations
	Mean pause segment duration	Average of all pause segment durations
	Total speech time	Sum of all speech segment duration
	Pause rate	The number of pause segments per minute
	Percent of speech	The percentage of speech time out of total time
	Articulation rate	The number of syllables articulated per second
	Pitch range	90th percentile of individual's pitch values after excluding pitch-tracking errors

References

1.	Alzheimer's Association. *2020 Alzheimer's disease facts and figures*.; 2020. doi:10.1002/alz.12068

2.	Nicholas M, Obler L, Albert M, Goodglass H. Lexical Retrieval in Healthy Aging. *Cortex*. 1985;21(4):595-606. doi:10.1016/S0010-9452(58)80007-6

3.	Henry ML, Gorno-Tempini ML. The logopenic variant of primary progressive aphasia. *Current opinion in Neurology*. 2010;23(6):633-637. doi:10.1097/WCO.0b013e32833fb93e.The

4.	Gorno-Tempini ML, Brambati SM, Ginex V, et al. The logopenic/phonological variant of primary progressive aphasia. *Neurology*. 2008;71:1227-1234.

5.	Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of Primary Progressive Aphasia. *Annals of Neurology*. 2004;55:335-346.

6.	Rohrer JD, Rossor MN, Warren JD. Alzheimer's pathology in primary progressive aphasia. *Neurobiology of Aging*. 2012;33(4):744-752. doi:10.1016/j.neurobiolaging.2010.05.020

7.	Gefen T, Gasho K, Rademaker A, et al. Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. *Brain*. 2012;135(5):1554-1565. doi:10.1093/brain/aws076

8.	Leyton CE, Britton AK, Hodges JR, Halliday GM, Kril JJ. Distinctive pathological mechanisms involved in primary progressive aphasias. *Neurobiology of Aging*. 2016;38:82-92. doi:10.1016/j.neurobiolaging.2015.10.017

9.   Giannini LAA, Irwin DJ, Mcmillan CT, et al. Clinical marker for Alzheimer disease

pathology in logopenic primary progressive aphasia. *Neurology*. 2017;88(24):2276-2284.

doi:10.1212/WNL.0000000000004034

10.   Bergeron D, Gorno-Tempini ML, Rabinovici GD, et al. Prevalence of amyloid-β

pathology in distinct variants of primary progressive aphasia. *Annals of Neurology*.

2018;84(5):729-740. doi:10.1002/ana.25333

11.   Wilson SM, Henry ML, Besbris M, et al. Connected speech production in three variants

of primary progressive aphasia. *Brain*. 2010;133:2069-2088. doi:10.1093/brain/awq129

12.   Johnson JCS, Jiang J, Bond RL, et al. Impaired phonemic discrimination in logopenic

variant primary progressive aphasia. 2020:1-6. doi:10.1002/acn3.51101

13.   Ash S, Evans E, O'Shea J, et al. Differentiating primary progressive aphasias in a brief

sample of connected speech. *Neurology*. 2013;81(4):329-336.

doi:10.1212/WNL.0b013e31829c5d0e

14.   Fraser K, Meltzer JA, Rudzicz F. Linguistic features identify Alzheimer's disease in

narrative speech. *Journal of Alzheimer's Disease*. 2016;49(2):407-422. doi:10.3233/JAD-150520

15.   Bucks RS, Singh S, Cuerden JM, Wilcock GK. Analysis of spontaneous, conversational

speech in dementia of Alzheimer type: Evaluation of an objective technique for analysing lexical

performance. *Aphasiology*. 2000;14(1):71-91. doi:10.1080/026870300401603

16.   Rentoumi V, Paliouras G, Danasi E, et al. Automatic detection of linguistic indicators as

a means of early detection of Alzheimer's disease and of related dementias: A computational

linguistics analysis. In: *8th IEEE International Conference on Cognitive Infocommunications,*

CogInfoCom 2017.; 2017:33-38. doi:10.1109/CogInfoCom.2017.8268212

17.   Hernández-Domínguez L, Ratté S, Sierra-Martínez G, Roche-Bergua A. Computer-based

evaluation of Alzheimer's disease and mild cognitive impairment patients during a picture

description task. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*.

2018;10:260-268. doi:10.1016/j.dadm.2018.02.004

18.   Eyigoz E, Courson M, Sedeño L, et al. From discourse to pathology: Automatic

identification of Parkinson's disease patients via morphological measures across three languages.

Cortex. 2020;132:191-205. doi:10.1016/j.cortex.2020.08.020

19.   Irwin D, McMillan CT, Toledo JB, et al. Comparison of cerebrospinal fluid levels of tau

and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.

Archives of Neurology. 2012;69(8):1018-1025. doi:10.1001/archneurol.2012.26

20.   Lleó A, Irwin DJ, Illán-Gala I, et al. A 2-step cerebrospinal algorithm for the selection of

frontotemporal lobar degeneration subtypes. *JAMA Neurology*. 2018;75(6):738-745.

doi:10.1001/jamaneurol.2018.0118

21.   Goodglass H, Kaplan E, Weintraub S. *Boston Diagnostic Aphasia Examination*. (Febiger

L&, ed.). Philadelphia; 1983.

22.   Honnibal M, Johnson M. An improved non-monotonic transition system for dependency

parsing. In: *EMNLP 2015: Conference on Empirical Methods in Natural Language Processing*.;

2015:1373-1378. doi:10.18653/v1/d15-1162

23.   Brysbaert M, Warriner AB, Kuperman V. Concreteness ratings for 40 thousand generally

known English word lemmas. *Behavior Research Methods*. 2014;46(3):904-911.

doi:10.3758/s13428-013-0403-5

24.   Hoffman P, Lambon Ralph MA, Rogers TT. Semantic diversity: A measure of semantic

ambiguity based on variability in the contextual usage of words. *Behavior Research Methods*.

2013;45(3):718-730. doi:10.3758/s13428-012-0278-x

25.   Brysbaert M, New B. Moving beyond Kučera and Francis: A critical evaluation of

current word frequency norms and the introduction of a new and improved word frequency

measure for American English. *Behavior Research Methods*. 2009;41(4):977-990.

doi:10.3758/BRM.41.4.977

26.   Brysbaert M, Mandera P, Keuleers E. Word prevalence norms for 62 ,000 English

lemmas. *Behavior Research Methods*. 2018;(July 2018):467-479.

27.   Carnegie Mellon Speech Group. The Carnegie Mellon University Pronouncing

Dictionary. 2014. http://www.speech.cs.cmu.edu/cgi-bin/cmudict.

28.   Covington MA, McFall JD. Cutting the Gordian knot: The movingaverage type-token

ratio (MATTR). *Journal of Quantitative Linguistics*. 2010;17(2):94-100.

29.   Fergadiotis G, Wright HH, Green SB. Psychometric evaluation of lexical diversity

indices: Assessing length effects. *Journal of Speech, Language, and Hearing Research*.

2015;58:840-852. doi:10.1044/2015

30.   Cho S, Nevler N, Ash S, et al. Automated analysis of lexical features in Frontotemporal

Degeneration. *Cortex*. 2021;137:215-231. doi:10.1016/j.cortex.2021.01.012

31.   Boersma P, Weenink D. Praat: doing phonetics by computer. 2019.

32.   Nevler N, Ash S, Jester C, Irwin DJ, Liberman M, Grossman M. Automatic measurement

of prosody in behavioral variant FTD. *Neurology*. 2017;89:1-8.

33.   Irwin DJ, Lleó A, Xie SX, et al. Ante mortem cerebrospinal fluid tau levels correlate with

postmortem tau pathology in frontotemporal lobar degeneration. *Annals of Neurology*.

2017;82(2):247-258. doi:10.1002/ana.24996

34.   R Core Team. R: A language and environment for statistical computing. 2019.

35.   RStudio Team. RStudio: Integrated Development for R. 2020. http://www.rstudio.com/.

36.   Levelt WJM. *Speaking: From intention to articulation*. Cambridge, MA: MIT Press;

1989.

37.   Pollock J-Y. Verb movement, universal grammar, and the structure of IP. *Linguistic*

Inquiry. 1989;20(3):365-424.

38.   Ash S, McMillan C, Gross RG, et al. Impairments of speech fluency in Lewy Body

Spectrum Disorder. *Brain and Language*. 2013;120(3):290-302.

doi:10.1016/j.bandl.2011.09.004.Impairments

39.   Gorno-Tempini ML, Hillis A, Weintraub S, et al. Classification of primary progressive

aphasia and its variants. *Neurology*. 2011;76(11):1006-1014.

40.   Croisile B, Ska B, Brabant MJ, et al. Comparative study of oral and written picture

description in patients with Alzheimer's disease. *Brain and Language*. 1996;53(1):1-19.

doi:10.1006/brln.1996.0033

41.   Kavé G, Goral M. Word retrieval in picture descriptions produced by individuals with

Alzheimer's disease. *Journal of Clinical and Experimental Neuropsychology*. 2016;38(9):958-

966. doi:10.1080/13803395.2016.1179266

42.   Kavé G, Dassa A. Severity of Alzheimer's disease and language features in picture

descriptions. *Aphasiology*. 2018;32(1):27-40. doi:10.1080/02687038.2017.1303441

43.   Buxbaum LJ, Schwartz MF, Carew TG. The Role of Semantic Memory in Object Use.

Cognitive Neuropsychology. 1997;14(2):219-254. doi:10.1080/026432997381565

44.   Kempler D. Lexical and pantomine abilities in Alzheimer's disease. *Aphasiology*.

1988;2(2):147-159. doi:10.1080/02687038808248900

45.   Ochipa C, Rothi LJG, Heilman KM. Conceptual apraxia in alzheimer's disease. *Brain*.

1992;115(4):1061-1071. doi:10.1093/brain/115.4.1061

46.   Adlam ALR, Bozeat S, Arnold R, Watson P, Hodges JR. Semantic knowledge in mild

cognitive impairment and mild Alzheimer's disease. *Cortex*. 2006;42(5):675-684.

doi:10.1016/S0010-9452(08)70404-0

47.   Giffard B, Desgranges B, Nore-Mary F, et al. The nature of semantic memory deficits in

Alzheimer's disease: New insights from hyperpriming effects. *Brain*. 2001;124(8):1522-1532.

doi:10.1093/brain/124.8.1522

48.   Venneri A, McGeown WJ, Hietanen HM, Guerrini C, Ellis AW, Shanks MF. The

anatomical bases of semantic retrieval deficits in early Alzheimer's disease. *Neuropsychologia*.

2008;46(2):497-510. doi:10.1016/j.neuropsychologia.2007.08.026

49. Huber CM, Yee C, May T, Dhanala A, Mitchell CS. Cognitive Decline in Preclinical

Alzheimer's Disease: Amyloid-Beta versus Tauopathy. *Journal of Alzheimer's Disease*.

2018;61(1):265-281. doi:10.3233/JAD-170490

50. Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological

aging in prospectively studied nondemented elderly humans. *Neurobiology of Aging*.

1992;13(1):179-189. doi:10.1016/0197-4580(92)90027-U

51. Engelborghs S, Maertens K, Vloeberghs E, et al. Neuropsychological and behavioural

correlates of CSF biomarkers in dementia. *Neurochemistry International*. 2006;48(4):286-295.

doi:10.1016/j.neuint.2005.11.002